Multicenter Phase 1b/2 Trial of TAS-102 with Bevacizumab in Patients with Metastatic Colorectal Cancer (mCRC) who had the progression or intolerant to standard therapies.
Phase of Trial: Phase I/II
Latest Information Update: 28 Jul 2017
Price : $35 *
At a glance
- Drugs Tipiracil/trifluridine (Primary) ; Bevacizumab
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms C-TASK FORCE
- 28 Jul 2017 Primary endpoint (4 month progression free survival by central assessment) has been met, as per results published in the Lancet Oncology.
- 28 Jul 2017 Results published in the Lancet Oncology
- 07 Aug 2015 Status changed from active, no longer recruiting to completed as per University Hospital Medical Information Network - Japan record.